NME4 and sarcoma: In six carcinoma types (breast, ovarian, lung, pancreatic, uterine, and esophageal carcinoma), low expression of NME4 was associated with a poor prognosis (Fig. 9C–H); this is also the case for tumors other than carcinomas such as pheochromocytoma, paraganglioma, and sarcoma (Fig. 9IJ).